# Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

> **NCT00308243** · PHASE1 · COMPLETED · sponsor: **Emphycorp** · enrollment: 15 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Sodium Pyruvate in 0.9% Sodium Chloride Solution

## Key facts

- **NCT ID:** NCT00308243
- **Lead sponsor:** Emphycorp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2011-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00308243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00308243, "Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00308243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*